Grant: Collaborative Research and Development Grants
University of Guelph
$54,484.00
Pre-clinical evaluation of the efficacy of combined THC and CBDA to treat nausea, pain and anxiety in veterinary medicine
EF 2015-16
Résumé
The cannabis plant has been used to treat nausea, pain and anxiety for thousand of years. However, it wasn't until the 1960's that scientists at the Hebrew University of Jerusalem discovered the psychoactive ingredient in cannabis, delta-9-tetrahydrocannabinol (THC) and other non-psychoactive cannabinoids, cannabidiol (CBD) and cannabidiolic acid (CBDA) in the plant. It is now known that the cannabis plant contains over 60 chemicals that have closely related structures, called cannabinoids, but the only mood altering consititutent is THC. Recent pre-clinical research using rat models of nausea has revealed that both THC and CBD are highly effective in reducing toxin-induced acute nausea and anticipatory nausea (as seen in chemotherapy patients when they return to the treatment clinic). They are also both effective in reducing inflammatory pain. THC produces a dose-dependent effect in animal models of anxiety-like behaviour, with low doses reducing anxiety and high doses increasing anxiety. CBD reduces anxiety across doses in animal models and has been shown to reverse the anxiety produced by high doses of THC. Most recently, the acidic precursor to CBD, CBDA that is in the plant before it is heated, has been found to be nearly 1000 times more potent than CBD in reducing acute and anticipatory nausea in animal models, without showing any effect on general motor activity level; therefore, CBDA may have considerable therapeutic potential in treating nausea in veterinary medicine. However, CBDA has not been evaluated for its effect on inflammatory pain or on anxiety. The therapeutic potential of combined ratios of THC and CBDA have not been systematically evaluated. The present studies aim to evaluate combined ratios of THC and CBDA (as well as each compound separately) in their ability to suppress acute and anticipatory nausea, inflammatory pain and anxiety in rodent models. These studies may potentially provide the pre-clinical evidence for the development of veterinary medicines to test in future clinical trials with companion animals.
Programme
Collaborative Research and Development Grants
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
476416-2014
Name nom
Parker, Linda
Department département
Psychology
Organization id
24
Institution établissement
University of Guelph
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2015
Competition year année de concours
2014
Award amount
54484
Program id
CRDPJ
Program name en
Collaborative Research and Development Grants
Program name fr
Subventions de recherche et développement coopérative
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
102
Area of application group en
Agriculture and primary food production
Area of application group fr
Agriculture et produits alimentaires primaires
Area of application en
Animal management (animal diseases, breeding)
Area of application fr
Gestion des animaux (maladies animales, reproduction)
Research subject code
6308
Research subject group en
Psychology
Research subject group fr
Psychologie
Research subject en
Behavioural neuroscience
Research subject fr
Neurologie du comportement
Partie
1
Nb partie
2
Application title
Pre-clinical evaluation of the efficacy of combined THC and CBDA to treat nausea, pain and anxiety in veterinary medicine
Keyword
NSERC
Application summary
The cannabis plant has been used to treat nausea, pain and anxiety for thousand of years. However, it wasn't until the 1960's that scientists at the Hebrew University of Jerusalem discovered the psychoactive ingredient in cannabis, delta-9-tetrahydrocannabinol (THC) and other non-psychoactive cannabinoids, cannabidiol (CBD) and cannabidiolic acid (CBDA) in the plant. It is now known that the cannabis plant contains over 60 chemicals that have closely related structures, called cannabinoids, but the only mood altering consititutent is THC. Recent pre-clinical research using rat models of nausea has revealed that both THC and CBD are highly effective in reducing toxin-induced acute nausea and anticipatory nausea (as seen in chemotherapy patients when they return to the treatment clinic). They are also both effective in reducing inflammatory pain. THC produces a dose-dependent effect in animal models of anxiety-like behaviour, with low doses reducing anxiety and high doses increasing anxiety. CBD reduces anxiety across doses in animal models and has been shown to reverse the anxiety produced by high doses of THC. Most recently, the acidic precursor to CBD, CBDA that is in the plant before it is heated, has been found to be nearly 1000 times more potent than CBD in reducing acute and anticipatory nausea in animal models, without showing any effect on general motor activity level; therefore, CBDA may have considerable therapeutic potential in treating nausea in veterinary medicine. However, CBDA has not been evaluated for its effect on inflammatory pain or on anxiety. The therapeutic potential of combined ratios of THC and CBDA have not been systematically evaluated. The present studies aim to evaluate combined ratios of THC and CBDA (as well as each compound separately) in their ability to suppress acute and anticipatory nausea, inflammatory pain and anxiety in rodent models. These studies may potentially provide the pre-clinical evidence for the development of veterinary medicines to test in future clinical trials with companion animals.